Search

Displaying results 2441 - 2450 of 10000 in total
  1. Drug

    Pralatrexate

    go.drugbank.com/drugs/DB06813
    ApprovedInvestigational

    [A246703] Pralatrexate was approved by the FDA on September 24, 2009. … [A246693] Compared to methotrexate, pralatrexate has better accumulation in cancer cells.

    Synonyms: N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid, (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid
  2. Drug

    Enflurane

    go.drugbank.com/drugs/DB00228
    ApprovedVet approvedWithdrawn

    In addition, it is known to cause increased cardio depressant effects when compared to other inhaled anesthetics.[A202022] … Enflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market.

  3. Drug

    Imipenem

    go.drugbank.com/drugs/DB01598
    ApprovedInvestigational

    [A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA. … Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628]

    Synonyms: N-formimidoylthienamycin, N-formimidoyl thienamycinMixtures: IMIPENEM E CILASTATINA SUN, IMIPENEM E CILASTATINA SUN
  4. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment

  5. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary … Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate.

  6. Drug

    Iloperidone

    go.drugbank.com/drugs/DB04946
    ApprovedInvestigational

    Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009.

  7. Drug

    Sitaxentan

    go.drugbank.com/drugs/DB06268
    ApprovedWithdrawn

    In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity. … Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008.

  8. Drug

    Bromocriptine

    go.drugbank.com/drugs/DB01200
    ApprovedInvestigationalWithdrawn

    In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use. … Bromocriptine has been associated with pulmonary fibrosis, and can also cause sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly.

  9. Drug

    Albumin Aggregated

    go.drugbank.com/drugs/DB14230
    Approved

    Albumin aggregated is an ingredient in the DRAXIMAGE MAA kit for the preparation of technetium tc99m albumin aggregated injection.

  10. Drug

    Promethazine

    go.drugbank.com/drugs/DB01069
    ApprovedInvestigational

    Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946.

    Synonyms: N,N,α-trimethyl-10H-phenothiazine-10-ethanamine, N,N,alpha-trimethyl-10H-phenothiazine-10-ethanamineMixtures: COPHADYL-E COUGH LINCTUS